Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.

Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Abstract Text:

Tamer A Elbayoumi,Vladimir P Torchilin,Tamer A Elbayoumi,Vladimir P Torchilin,Tamer A Elbayoumi,Vladimir P Torchilin,Tamer A Elbayoumi,Vladimir P Torchilin,Tamer A Elbayoumi,Vladimir P Torchilin,

Doxorubicin-loaded long-circulating liposomes (Doxiltrade mark, ALZA Corp.) were additionally modified with the nucleosome-specific monoclonal antibody 2C5 (mAb 2C5) recognizing a broad variety of tumor cells via the tumor cell surface-bound nucleosomes. These mAb 2C5-modified PEGylated liposomes demonstrated 3-8-fold increase in the in vitro binding and internalization by multiple cancer cell lines of diverse origins (murine LLC, 4T1, C26 and human BT-20, MCF-7, and PC3), as shown by flow cytometry (FACS) and epi and confocal microscopy. As a result, mAb 2C5-modified Doxiltrade mark demonstrated significantly higher cytotoxicity towards various cancer cells, including those resistant to doxorubicin, than all control preparations. The specific internalization of the mAb 2C5-Doxiltrade mark into cytosol, along with the nuclear localization of their drug load, inside the target cancer cells were mainly responsible the superior anticancer activity. The IC50 values of mAb 2C5-Doxiltrade mark with various murine and human cancer cells were 5-8-fold lower than those of control doxorubicin-loaded liposomes, Doxiltrade mark or Doxiltrade mark modified with a nonspecific IgG.

Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Publishing Authors By Initials

TA Elbayoumi,VP Torchilin,TA Elbayoumi,VP Torchilin,TA Elbayoumi,VP Torchilin,TA Elbayoumi,VP Torchilin,TA Elbayoumi,VP Torchilin,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of pharmaceutical sciences : offi

VOLUME: 32

Page Numbers: 159-68

Journal Abbreviation:

ISSN: 0928-0987

DAY: 7

MONTH: 06

YEAR: 2007

Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9317982

Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.

AFFILIATION: Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Pharm Sci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines Related Publications

• "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers.
• "Smart" Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes.
• Antibody-modified liposomes for cancer chemotherapy.
• Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
• Bioengineering and Imaging Research Opportunities Workshop V: A summary on Imaging and Characterizing Structure and Function in Native and Engineered Tissues.
• Bioengineering and Imaging Research Opportunities Workshop V: a white paper on imaging and characterizing structure and function in native and engineered tissues.
• Bioengineering and imaging research opportunities workshop V: summary of findings on imaging and characterizing structure and function in native and engineered tissues.
• Bioengineering and imaging research opportunities workshop v: a summary.
• Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates.
• Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
• Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
• Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes.
• Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes.
• Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy.
• Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: Improved drug solubilization and enhanced in vitro cytotoxicity.
• Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
• Nanocarriers.
• PEGylated dextran as long-circulating pharmaceutical carrier.
• Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.
• Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux.
• Polymeric contrast agents for medical imaging.
• Preface. Fifth International Nanomedicine and Drug Delivery Symposium (NanoDDS'07).
• Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction.
• Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology.
• Surface Modification of Pharmaceutical Nanocarriers with Ascorbate Residues Improves their Tumor-Cell Association and Killing and the Cytotoxic Action of Encapsulated Paclitaxel In Vitro.
• TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice.
• Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers.
• Tatp-mediated intracellular delivery of pharmaceutical nanocarriers.
• The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells.
• Tumor-specific antibody-mediated targeted delivery of Doxil((R)) reduces the manifestation of auricular erythema side effect in mice.